Title : Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.

Pub. Date : 2019 Jan

PMID : 30500458






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Osimertinib is an irreversible type VI inhibitor that forms a covalent bond with C797 of EGFR and is FDA-approved for the treatment of patients with this mutation; type VI inhibitors generally form a covalent adduct with their target protein. osimertinib epidermal growth factor receptor Homo sapiens
2 Of the approximate three dozen FDA-approved small molecule protein kinase inhibitors, five are type VI irreversible inhibitors and four of them including afatinib, osimertinib, dacomitinib, and neratinib are directed against the ErbB family of receptors (ibrutinib is the fifth and it targets Bruton tyrosine kinase). osimertinib epidermal growth factor receptor Homo sapiens